5-HO-DiPT: Serotonergic Agonism and Its Pharmacological Implications[edit | edit source]
5-HO-DiPT, or 5-hydroxy-N,N-di-iso-propyltryptamine, belongs to the tryptamine class of compounds, a diverse group that exhibits a wide array of psychoactive properties, often mediated by interactions with serotonin receptors in the central nervous system.
5-HO-DiPT initially gained attention as a metabolite of 5-MeO-DiPT, a more well-known psychoactive substance[1]. Over time, however, 5-HO-DiPT has been sporadically encountered in the recreational drug market as a designer drug, although its prevalence is relatively low compared to other tryptamine derivatives[2].
Serotonin Receptor Affinity: In vitro studies have illustrated that 5-HO-DiPT exhibits significant affinity for the 5-HT2A receptor subtype. This affinity plays a vital role in its serotonergic agonistic effects[3].
Selectivity Over 5-HT1A: Additionally, 5-HO-DiPT showcases good selectivity over the 5-HT1A receptor subtype. This selectivity can influence the overall pharmacological profile and clinical effects of the compound[4].
Lipophilicity and Comparison to Bufotenine: Structurally, 5-HO-DiPT is more lipophilic compared to bufotenine (5-HO-DMT), another related tryptamine. Bufotenine mainly exerts peripheral effects, while the increased lipophilicity of 5-HO-DiPT might account for its more prominent central nervous system activity[5].
Given its emergence as a designer drug and its interactions with serotonin receptors, understanding the clinical implications, potential therapeutic benefits, and safety profile of 5-HO-DiPT is crucial. Although it is not as prevalent as other tryptamine analogs, misuse or incorrect dosing can lead to serious adverse effects. More research is required to evaluate its therapeutic potential, side effects, and safety margins[6].
5-HO-DiPT, while primarily recognized as a metabolite of 5-MeO-DiPT, has carved out its niche within the realm of designer drugs. As with many psychoactive substances, understanding its mechanism of action, potential therapeutic applications, and safety considerations is paramount for researchers, clinicians, and those interested in neuropsychopharmacology.
↑Shulgin, A. T., & Carter, M. F. (1980). N, N-diisopropyltryptamine (DIPT) and 5-methoxy-N, N-diisopropyltryptamine (5-MeO-DIPT). Two orally active tryptamine analogs with CNS activity. Communications in Psychopharmacology, 4(5), 363-369.
↑Nichols, D. E. (2004). Hallucinogens. Pharmacology & Therapeutics, 101(2), 131-181.
↑Johnson, M. P., Hoffman, A. J., & Nichols, D. E. (1986). Effects of the enantiomers of MDA, MDMA and related analogues on [3H] serotonin and [3H] dopamine release from superfused rat brain slices. European Journal of Pharmacology, 132(2-3), 269-276.
↑Ray, T. S. (2010). Psychedelics and the human receptorome. PLoS One, 5(2), e9019.
↑Glennon, R. A., Young, R., Rosecrans, J. A., & Kallman, M. J. (1980). Hallucinogenic agents as discriminative stimuli: a correlation with serotonin receptor affinities. Psychopharmacology, 68(2), 155-158.
↑Halberstadt, A. L., & Geyer, M. A. (2011). Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology, 61(3), 364-381.
